Acta ophthalmologica · 2026
Intravitreal faricimab in patients with nAMD: French data from the Fight Retinal Blindness! Registry.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Debourdeau Eloi, Harboun Déborah, Gabrielle Pierre-Henry, Hashimoto Yohei, Chamard Chloe, Michon Frederic, Wolff Benjamin, Torres-Villaros Héloïse, Giocanti-Auregan Audrey, Gillies Mark, Creuzot-Garcher Catherine, Daien Vincent
Аннотация
PURPOSE: To assess real-world outcomes of intravitreal faricimab in French patients with neovascular age-related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.
METHODS: Retrospective analysis of prospectively collected FRB! Registry data (November 2023-March 2026) on eyes switched to faricimab from other VEGF inhibitors.
PRIMARY ENDPOINT: change in injection interval at 12 months. Secondary endpoints: macular neovascularization (MNV) inactivation, visual acuity (VA), injections, switch-off, safety. Mixed-effects models assessed baseline predictors of interval change and loading-dose effect on MNV inactivation.
RESULTS: We included 222 eyes (169 patients; mean [SD] age 81.4 [7.8] years; VA 64.6 [19.3] letters; interval 5.9 [3.5] weeks; 26.2 prior injections); 143 (64.4%) were 12-month completers. Mean interval increased from 6.0 to 8.4 weeks (p < 0.001), with a greater gain in inactive (Δ +4.0 weeks) than active eyes (Δ +1.7 weeks; p = 0.033). VA remained stable (Δ -0.8 letters; p = 0.28). Inactive MNV rose from 36% to 60% (p < 0.001); 50% of active eyes achieved inactivation. After adjustment, MNV activity at switch was the only predictor of interval reduction (vs. inactive: SRFl only, β = -2.8 weeks, p = 0.015; IRF/haemorrhage, β = -2.4 weeks, p = 0.020). A loading dose was not associated with interval extension (p = 0.59) or MNV inactivation (p = 0.50). Intraocular inflammation occurred in 5 eyes (2.3%).
CONCLUSION: Macular neovascularization (MNV) inactivation and modest interval extension were observed in active eyes; inactive eyes showed a larger interval extension. Loading dose was not associated with better outcomes in this observational cohort. Safety was acceptable.
METHODS: Retrospective analysis of prospectively collected FRB! Registry data (November 2023-March 2026) on eyes switched to faricimab from other VEGF inhibitors.
PRIMARY ENDPOINT: change in injection interval at 12 months. Secondary endpoints: macular neovascularization (MNV) inactivation, visual acuity (VA), injections, switch-off, safety. Mixed-effects models assessed baseline predictors of interval change and loading-dose effect on MNV inactivation.
RESULTS: We included 222 eyes (169 patients; mean [SD] age 81.4 [7.8] years; VA 64.6 [19.3] letters; interval 5.9 [3.5] weeks; 26.2 prior injections); 143 (64.4%) were 12-month completers. Mean interval increased from 6.0 to 8.4 weeks (p < 0.001), with a greater gain in inactive (Δ +4.0 weeks) than active eyes (Δ +1.7 weeks; p = 0.033). VA remained stable (Δ -0.8 letters; p = 0.28). Inactive MNV rose from 36% to 60% (p < 0.001); 50% of active eyes achieved inactivation. After adjustment, MNV activity at switch was the only predictor of interval reduction (vs. inactive: SRFl only, β = -2.8 weeks, p = 0.015; IRF/haemorrhage, β = -2.4 weeks, p = 0.020). A loading dose was not associated with interval extension (p = 0.59) or MNV inactivation (p = 0.50). Intraocular inflammation occurred in 5 eyes (2.3%).
CONCLUSION: Macular neovascularization (MNV) inactivation and modest interval extension were observed in active eyes; inactive eyes showed a larger interval extension. Loading dose was not associated with better outcomes in this observational cohort. Safety was acceptable.